Valuation: Verastem, Inc.

Market Cap 528M 464M 433M 398M 744M 50.59B 763M 5.14B 2.01B 25.03B 1.98B 1.94B 86.53B P/E 2026 *
-3.8x
P/E 2027 * -5.36x
Enterprise Value 363M 319M 298M 273M 512M 34.78B 524M 3.53B 1.38B 17.21B 1.36B 1.33B 59.5B EV / Sales 2026 *
3.56x
EV / Sales 2027 * 1.79x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-3.53%
1 week+2.04%
Current month+57.33%
1 month+57.33%
3 months+11.30%
6 months-6.24%
Current year-22.15%
1 week 5.82
Extreme 5.82
6.46
1 month 3.84
Extreme 3.835
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
6/22/26 A Sell

Chief Executive Officer

-20,871 0.0339%
6/22/26 A Sell

Chief Financial Officer

-4,089 0.0066%
5/21/26 A Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-3.53%+2.04%-4.45%-41.65% 528M
-2.60%-5.22%+44.38%+65.30% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
+0.54%+1.22%-16.62%-13.47% 23.51B
-0.97%-3.30%-1.79%+383.00% 22.35B
-4.01%-3.67%+13.17%-14.29% 20.6B
-1.70%-3.49%+25.56%-34.07% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-2.09%+0.64%+49.78%+178.74% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -1.80%-0.76%+32.74%+143.50% 23.81B
Weighted average by Cap. -0.98%-0.51%+32.03%+126.73%

Financials

2026 *2027 *
Net sales 102M 89.51M 83.55M 76.68M 144M 9.76B 147M 991M 387M 4.83B 382M 374M 16.69B 178M 157M 146M 134M 251M 17.08B 257M 1.73B 678M 8.45B 670M 655M 29.22B
Net income -166M -145M -136M -125M -233M -15.85B -239M -1.61B -630M -7.85B -621M -608M -27.12B -142M -125M -117M -107M -200M -13.61B -205M -1.38B -540M -6.73B -533M -522M -23.28B
Net Debt -165M -145M -135M -124M -232M -15.8B -238M -1.6B -628M -7.82B -619M -606M -27.04B -210M -184M -172M -158M -295M -20.08B -303M -2.04B -797M -9.93B -787M -770M -34.34B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
29/07/26 $6.010 -3.53% 2,249,888
28/07/26 $6.230 +2.47% 1,275,019
27/07/26 $6.080 +0.50% 2,244,215
24/07/26 $6.050 -2.10% 2,531,721
23/07/26 $6.180 +4.92% 2,193,680
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.010USD
Average target price
15.00USD
Spread / Average Target
+149.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock